Celltrion Pharm Inc Cash Flow-to-Debt Ratio
Celltrion Pharm Inc cash flow-to-debt ratio. Celltrion Pharm Inc (068760) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of ₩23.44 Billion could theoretically repay 0% of its total liabilities (₩319.38 Billion) in one year. Check how high is Celltrion Pharm Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Celltrion Pharm Inc (2014–2024)
Cash flow-to-debt ratio of Celltrion Pharm Inc from 2014 to 2024. Historical debt coverage capacity for Celltrion Pharm Inc across 11 annual periods. Check 068760 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Celltrion Pharm Inc Cash Flow-to-Debt Ratio by Year (2014–2024)
Celltrion Pharm Inc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Celltrion Pharm Inc. For the full cash flow conversion analysis, see Celltrion Pharm Inc (068760) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩56.59 Billion | ₩272.54 Billion | ▲ +528.3% |
| 2023 | 0.03x | ₩8.76 Billion | ₩264.98 Billion | ▲ +298.4% |
| 2022 | -0.02x | ₩-4.05 Billion | ₩242.94 Billion | ▼ -105.5% |
| 2021 | 0.30x | ₩93.15 Billion | ₩305.92 Billion | ▲ +107.9% |
| 2020 | 0.15x | ₩36.25 Billion | ₩247.51 Billion | ▲ +0.4% |
| 2019 | 0.15x | ₩27.85 Billion | ₩190.95 Billion | ▲ +85.9% |
| 2018 | 0.08x | ₩14.31 Billion | ₩182.41 Billion | ▲ +236.4% |
| 2017 | -0.06x | ₩-10.16 Billion | ₩176.65 Billion | ▲ +37.5% |
| 2016 | -0.09x | ₩-15.21 Billion | ₩165.37 Billion | ▼ -258.7% |
| 2015 | 0.06x | ₩13.36 Billion | ₩230.54 Billion | ▼ -34.2% |
| 2014 | 0.09x | ₩17.33 Billion | ₩196.74 Billion | — |